AngioDynamics, Inc. (NASDAQ:ANGO)‘s stock had its “hold” rating reiterated by research analysts at KeyCorp in a note issued to investors on Friday. KeyCorp also issued estimates for AngioDynamics’ Q2 2018 earnings at $0.16 EPS and Q4 2018 earnings at $0.23 EPS.

Several other equities research analysts have also recently commented on ANGO. BidaskClub cut AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Cantor Fitzgerald boosted their target price on AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. Canaccord Genuity restated a “hold” rating and issued a $17.00 target price on shares of AngioDynamics in a research note on Tuesday, July 18th. Finally, Barclays PLC cut their target price on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 19th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $18.60.

AngioDynamics (NASDAQ ANGO) opened at 17.09 on Friday. The company has a 50-day moving average price of $17.00 and a 200-day moving average price of $16.31. The firm has a market cap of $625.15 million, a P/E ratio of 124.74 and a beta of 1.14. AngioDynamics has a 12-month low of $14.80 and a 12-month high of $18.35.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The firm had revenue of $85.40 million during the quarter, compared to the consensus estimate of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The company’s revenue was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 EPS. On average, analysts predict that AngioDynamics will post $0.66 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/01/angiodynamics-inc-ango-rating-reiterated-by-keycorp.html.

In related news, CEO James C. Clemmer purchased 20,000 shares of the stock in a transaction on Thursday, July 20th. The shares were purchased at an average price of $15.64 per share, with a total value of $312,800.00. Following the transaction, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO James C. Clemmer purchased 5,000 shares of the stock in a transaction on Friday, July 21st. The shares were bought at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at $1,368,724.57. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,316 shares of company stock worth $396,806 in the last ninety days. Insiders own 1.80% of the company’s stock.

Several large investors have recently bought and sold shares of ANGO. Janus Henderson Group PLC acquired a new position in shares of AngioDynamics during the 2nd quarter worth approximately $15,619,000. Peregrine Capital Management LLC acquired a new position in shares of AngioDynamics during the 2nd quarter worth approximately $12,133,000. Wells Fargo & Company MN increased its position in shares of AngioDynamics by 86.3% during the 2nd quarter. Wells Fargo & Company MN now owns 1,015,594 shares of the medical instruments supplier’s stock worth $16,463,000 after purchasing an additional 470,522 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in shares of AngioDynamics during the 2nd quarter worth approximately $6,727,000. Finally, Vanguard Group Inc. increased its position in shares of AngioDynamics by 14.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,938,115 shares of the medical instruments supplier’s stock worth $31,416,000 after purchasing an additional 243,825 shares during the last quarter. 95.71% of the stock is currently owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Stock Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related stocks with our FREE daily email newsletter.